Summary. Peripheral blood lymphocytes of 46 recipients of lymphocyte-depleted bone marrow allografts were phenotypically analysed over a period of 1 year. We investigated the repopulation of lymphocyte subpopulations and their relation with clinical parameters such as graft-versus-host disease (GVHD), graft-versus-leukaemia and cytomegalo virus (CMV) infection. The number of repopulated T cells varied strongly between the blood samples of the recipients. In 45% of the recipients the number of T cells recovered to or above normal levels within 3 months after bone marrow transplantation (BMT), whereas the other recipients remained below normal up to 1 year after BMT. In recipients with a high repopulation, the CD8+ T-cell subset contributed more to this high repopulation than the CD4+ Tcell subset. We showed that the majority of T cells of these recipients expressed the a ( 3 T-cell receptor, CD8, CD 5 7 and CDllb. HLA-DR was also highly expressed reflecting the activation stage of T cells in these recipients. BMT recipients with a high repopulation of CD8+ T cells showed a lower incidence of leukaemic relapse than recipients with a low repopulation. The 3-year probability of relapse was 19% versus 64% (P = 0-03), respectively. The relative high number of CD8+ T cells at 3 months after BMT was not associated with the incidence of GVHD. In contrast, occurrence of CMV infection after BMT was significantly higher in these recipients. Our results indicate that CD8+ T cells, predominantly CD57+, of BMT recipients with an expansion of these cells represent an in vivo activated cell population. This CD8+ T-cell population may consist partially of cytotoxic cells with anti-leukaemic activity as suggested by a low relapse rate. The signal for the strong expansion of these CD8+CD57+ T cells after BMT is still unclear, but association with CMV infection suggests that viral antigens are involved.
Allogeneic bone marrow transplantation (BMT) is an effective treatment for
with leukaemia that been associated with graft-versus-leukaemia (GVL) activity (Hor owitz et al, 1990 ). Donor-derived cytotoxic effector cells appear to be involved in the elimination of residual leukaemic cells after BMT. Graft-versus-host disease (GVHD) is an adverse complication of allogeneic BMT, but is associated with this GVL activity (Horowitz et a l 1990). T-cell depletion of the graft reduces the incidence and severity of acute GVHD (De Witte et al, 1984) , but unfortunately results in higher relapse rate (Horowitz et al, 1990) 
. Cytomegalovirus (CMV) infection has
CorrevSpondence: Dr H. Dolstra, Division of Haematology, Department of Internal Medicine, University Hospital Nijmegen, Geert Grooteplein 8, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. also been suggested to be associated with decreased incidence of leukaemic relapse (Ringden, 1992) . These data indicate that alloantigens and viral antigens may induce cell populations that mediate GVL activity after BMT.
CMV is frequently reactivated after allogeneic BMT and the onset of CMV infection is during the first 3 months. CMV profoundly stimulates CD8+ T cells which represent the majority of T cells in the blood of BMT recipients (Leroy et al, 1986; Wursch et al, 1985; Yabe et al, 1990) . Polyclonal stimulation of CD8+ cytotoxic T lymphocytes (CTL) occurs during viral infections (Nahill & Welsh, 1993). Reconstitu tion of CD8+ CMV-specific CTL response, during CMV infection after BMT, provides protection from the develop ment of CMV disease (Reusser et al, 1991) . Most CD8+ T cells in BMT recipients express the CDS 7 antigen, whereas in 300 © 1995 Blackwell Science Ltd T-cell Expansion after BMT 301 healthy individuals CD8+CD57 T are a minor lymphocyte subpopulation (Leroy el al, 1986; Wursch et al, 1985; Yabe et al, .1990; Izquierdo et al, 1990; Fukuda et al, 1994) . This expression of the CD57 antigen on T cells appears to be a hallmark of CMV infection (Wursch et al, 1985; Gratama et al, 1988; Autran et al, 1991; Labalette et al, 1994) .
In this study we investigated reconstitution of peripheral blood lymphocyte (PBL) subpopulations in recipients of lymphocyte-depleted bone marrow allografts. We observed that the absolute number of T cells, of which the majority express TCRck/?, CD8 and CD57, returned to normal levels in approximately half of the recipients within 3 months after BMT. In contrast, T-cell numbers in the other recipients remained below normal for at least 1 year. The high repopulation of CDS1 T cells in BMT recipients was associated with a low relapse rate and with CMV infection. Therefore we suggest that the CD8+ T-cell population, predominantly CD57+, contains cytotoxic cells that obtain GVL activity during CMV infection after BMT. Statistical analysis. Absolute numbers of lymphocyte subpopulations of BMT recipients and normal individuals were compared using the non-parametric Mann-Whitney Utest. Correlations between absolute numbers of lymphocyte subpopulations at different time periods after BMT were analysed with the Spearman's rank test. Relapse and survival analysis was performed using the Kaplan-Meier product-limit method. Actuarial curves were calculated for relapse, survival and leukaemia-free survival (LFS) and the effect of high repopulation of T cells on the curves was compared using the log-rank test. The Fisher's exact test was used to assess differences in clinical parameters. For all tests P value <0-05 was considered significant.
MATERIALS AND METHODS

Patient
RESULTS
Phenotypic analysis of lymphocytes after BMT
PBL of BMT recipients were analysed by FCM at several time periods until 1 year postgrafting. Fig .1 shows the absolute number of repopulated lymphocyte subpopulations in comparison with lymphocyte numbers of normal individuals. The median number of both NK cells and T cells were below the normal range for at least 1 year. The median number of CD8+ T cells was also below normal at 1 month, but increased to normal within 3 months. CD4+ T cells repopulated very slowly and the median number remained below normal during the whole follow-up period. Almost all CD4+ cells coexpressed CD45RO corresponding with a helper and memory phenotype (data not shown). The percentage of NK cells was higher than normal at 1 month after BMT, but by increasing numbers of T cells this returned gradually to normal during the subsequent months. The absolute number of T cells at 3 months after BMT was strongly correlated with coexpression of the CD 5 7 antigen on these cells (Fig 2; r -0-70, P < 0-001) . To determine coexpression of other antigens on T cells, PBL of five BMT recipients with a high repopulation of T cells were additionally characterized (Fig 3) . The majority of these T cells expressed both CD8 and CD5 7 (68-88%).
90% of T cells expressed the a/3 T-cell receptor (87-98%). In all five patients studied, <30% of T cells expressed CD4. Further more, we studied the expression on these cells of EL-2 receptor a-chain (CD25) and HLA-DR because both antigens are associated with T-cell activation. A small percentage of T cells expressed CD25 (1-16%), whereas HLA-DR was expressed on 48-76% of T cells. C D llb which is frequently coexpressed with CD5 7 on lymphocytes after BMT (Yabe et al,
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T cells (x10 /I) On the basis of the difference in repopulation of CD8+ T cells, patients were divided in two groups. The median number of CD8+ T cells at 3 months after BMT was 0-28 x 109/1 (range 0 -0 2 -3 -8 7 x 109/1). This value was chosen retrospectively as a cut-off point to divide the patients in two equally sized groups. The mean number of CD8+ T cells at 3 months after BMT in group 1 (2 4 /4 6 patients) was strongly below normal CD8+ T-cell numbers (0-14 ± 0-08 x 109/1 and 0-42 ± 0-14 x 109/1, respec tively; P < 0-001; Fig 1, closed circles) . The mean number of CD8+ T cells at 3 months after BMT in group 2 (22/46 patients) was above normal levels (1-06 ± 0-92 x 199/1 and 0-42 ± 0 -1 4 x 1 0 9/1, respectively; P < 0-001; Fig 1, open  circles) .
These data demonstrate that in 45% of the recipients the number of CD8+ T cells recovered above normal levels within 3 months after BMT, whereas the other recipients remained strongly below normal levels.
Relationship between repopulation of CD8+ T cells and clinical data
To determine the contribution of CD8+ T-cell repopulation to the clinical outcome, clinical data of both patient groups were evaluated (Table I) . Patients with MM, SAA and RA as underlying disease and patients not in CR1 or CPI were not included in this evaluation. Both groups were not signifi cantly different with regard to age, sex, underlying disease, conditioning therapy and T cells/kg body weight trans planted. However, a significant difference could be found in the projected 3-year probability of relapse between patients transplanted in CR1/CP1 in groups 1 and 2, 64% versus 19% (P = 0-03, Fig 4A) . The probability of survival was not significantly different between the two groups ( Table I ). The projected 3-year probability of survival for group 1 was 61% and for group 2 63% (P = 0-64). No difference was found in transplant-related mortality (TRM) between groups 1 and 2, 10% versus 18% (P = 0-40), respectively. However, a trend was observed towards a longer leukaemia-free survival (LFS) for recipients in group 2 with a projected 3-year probability of LFS of 60% versus 34% for group 1 (P = 0-15, Fig 4B) . The projected 3-year probability of relapse, survival and LFS for all patients studied was 43%, 62% and 46%, respectively. No significant differences in acute and chronic GVHD were found between the two groups (Table I) . A positive CMV serologic determination of both recipient and donor prior to BMT was more frequently detected in group 2 than in group 1 (P = 0-001). Moreover, a negative CMV serologic determination of both recipient and donor prior to BMT was more frequently detected in group 1 than in group 2 (P = 0-001). The incidence of CMV infection after BMT was significantly higher in group 2 (12/17) than in group 1 (2 / 21, P < 0-001). The median time of onset of CMV infection was 9 weeks (range 5 -1 2 weeks). None of the patients studied developed CMV disease.
Although the probability of relapse and LFS for patients with CMV infection ( n = 14) versus patients without CMV infection (n = 24) showed differences, it was not statistically significant. The projected 3-year probability of relapse for patients with CMV infection was 23% and for patients without CMV infection 47% (P = 0 * 4 0 ). The projected 3-year probability of LFS for patients with CMV infection was 56% and for patients without CMV infection 45% (P = 0-92).
These data indicate that high repopulation of CD8+ T cells, predominantly CD 5 7+ , is related with a low incidence of leukaemic relapse. Moreover, high repopulation of CD8+ T cells is correlated with the occurrence of CMV, suggesting that viral antigens are involved. (1986) showed that patients with a CMV infection after BMT had a reduced risk of recurrent leukaemia. Moreover, transplantation of bone marrow from CMV seropositive donors resulted in lower incidence of leukaemic relapse (Jacobsen et al, 1986 ). Therefore we hypothesize that donor-derived CTL become activated during CMV infection which induces GVL activity. Prophylactic treatment with ganciclovir may lead to a delay in recovery of CMV-specific immunoresponse because of the absence of CMV infection (Li et al, 1994) . This prophylactic treatment for CMV infection could increase the incidence of leukaemic relapse.
Viral infections appear to stimulate the generation of alloantigen-specific CTL coincidental with the generation of virus-specific CTL (Nahill & Welsh, 1993; Yang et al, 1989; Tomkinson et al, 1989) . Nahill & Welsh (1993) reported that a high frequency of these CTL were cross-reactive for allogeneic and virus-infected syngeneic target cells. More over, CTL clones have been isolated specific for a HLA-B8 restricted Epstein-Barr virus epitope and cross-reactive with the alloantigen HLA-B44.02 (Burrows et al, 1994 ).
In conclusion, in this report we demonstrate that high repopulation of CD8+ T cells after lymphocyte-depleted allogeneic BMT is related with a lower relapse rate. Relation between CMV infection and high numbers of CD8+ T cells in BMT recipients suggests that CMV can be the signal for expansion of these cells. To elucidate the trigger for expansion of CD8+ T cells after BMT and the role of CD57, C D llb and HLA-DR antigens on these cells further studies are needed. Investigations whether donor-derived CTL show cross-reactivity against the recipient's leukaemic cells upon stimulation during CMV infection and determination of the specificity of these cells are in progress.
